@article{943b879c14c240a19ca268ec4a7be59d,
title = "Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation",
keywords = "Atrial fibrillation, Ablation, Oral anticoagulation, Apixaban, Warfarin, Un-interrupted, Stroke, Bleeding, ACADEMIC RESEARCH CONSORTIUM, PERIPROCEDURAL ANTICOAGULATION, RADIOFREQUENCY ABLATION, BLEEDING COMPLICATIONS, UNINTERRUPTED RIVAROXABAN, MEDICARE BENEFICIARIES, ORAL ANTICOAGULANTS, SAFETY, DABIGATRAN, MANAGEMENT",
author = "{Di Biase}, Luigi and David Callans and Haeusler, {Karl Georg} and Gerhard Hindricks and Hussein Al-Khalidi and Lluis Mont and Nielsen, {Jens Cosedis} and Piccini, {Jonathan P.} and Ulrich Schotten and Paulus Kirchhof",
year = "2017",
month = jan,
doi = "10.1093/europace/euw368",
language = "English",
volume = "19",
pages = "132--138",
journal = "EP Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "1",
}